Abstract-Cardiovascular disease remains the leading cause of death and disease worldwide. As demands on an already resource-constrained healthcare system intensify, disease prevention in the future will likely depend on out-of-office monitoring of cardiovascular risk factors. Mobile health tracking devices that can track blood pressure and heart rate, in addition to new cardiac vital signs, such as physical activity level and pulse wave velocity (PWV), offer a promising solution. An initial barrier is the development of accurate and easily-scalable platforms. In this study, we made a customized smartphone app and used mobile health devices to track PWV, blood pressure, heart rate, physical activity, sleep duration, and multiple lifestyle risk factors in ≈250 adults for 17 continual weeks. Eligible participants were identified by a company database and then were consented and enrolled using only a smartphone app, without any special training given. Study participants reported high overall satisfaction, and 73% of participants were able to measure blood pressure and PWV, <1 hour apart, for at least 14 of 17 weeks. The study population's blood pressure, PWV, heart rate, activity levels, sleep duration, and the interrelationships among these measurements were found to closely match either population averages or values obtained from studies performed in a controlled setting. As a proof-of-concept, we demonstrated the accuracy and ease, as well as many challenges, of using mHealth technology to accurately track PWV and new cardiovascular vital signs at home. (Hypertension. 2018;72:503-510.
C ardiovascular disease remains the leading cause of death and disease worldwide, responsible for ≈46% of noncommunicable disease deaths in 2012. 1 As demands on an already resource-constrained healthcare system intensify, disease prevention in the future will likely depend on out-of-office monitoring of cardiovascular risk factors. 2 Commercially available mobile health tracking devices that can continually track and wirelessly transmit blood pressure (BP) and heart rate (HR), in addition to new vital signs, such as physical activity level, sleep duration and pulse wave velocity, offers a promising solution. 2 An initial barrier is the development of accurate, easily-scalable, home monitoring platforms.
Pulse wave velocity (PWV) is a validated measure of arterial wall stiffness and one of the most important measures of cardiovascular risk. [3] [4] [5] [6] [7] [8] [9] [10] PWV has traditionally been measured in a controlled setting using a Sphygmometer and applanation tonometry but can now be accurately measured out-of-the-office using smart weight scales. 11, 12 Similarly, BP, a powerful contributor to cardiovascular disease, 13 is still measured predominantly in a clinical setting but can now be measured accurately at home using wireless BP monitors. In fact, the American College of Cardiology and American Heart Association 2017 guidelines recommend taking BP measurements at home, citing strong evidence that an individual's BP outside the clinical setting is more predictive of health outcomes. 14 American College of Cardiology/American Heart Association guidelines also recommend identifying and reversing other lifestyle cardiovascular risk factors. This goal is difficult to accomplish using physician office visits because patients often lie to physicians about their lifestyle behaviors, and there is limited face-to-face time between doctors and patients. 15 The use of new mobile health (mHealth) technologies to assess and track cardiovascular risk factors at home offers a promising solution to improve monitoring, help meet guideline recommendations, and offload some burden placed on healthcare systems. In this proof-of-concept study, we made a customized smartphone app and then used advanced mHealth technologies to determine the feasibility, accuracy, and ease of tracking an array of different cardiovascular risk factors at home.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request. Participants were enrolled and gave informed consent using a customized smartphone app with all protocols approved by an institutional review committee at Scripps Health (La Jolla, CA). There were 2 inclusion criteria. First, participants had to already own 3 health tracking devices: a mHealth BP monitor, an activity tracker, and a smart weight scale that can measure weight, HR, and PWV. Second, participants had to have measured their BP, on their own volition, at least once per week, for most weeks, over 3 months before enrollment. Owners of Withings health tracking devices had agreed to share their health tracking data with the company, and so eligible study participants were identified by querying a company database. Eligible participants were contacted for enrollment through a push message on the Withings Health Mate app ( Figure 1A ). Participants volunteered from the general public, and no exclusions were made based on sex, race, etc. Exclusion criteria included aortic artery disease, peripheral vascular disease, atrial fibrillation, weight >396 lbs. (scale weight limit) and pregnancy.
Participants provided demographic, medication usage, and medical history by completing a short survey, provided in Table S1 in the online-only Data Supplement. Stress levels were assessed using the validated Perceived Stress Scale survey. 16 Participants were asked to measure BP, HR, PWV, and weight 2 days per week for 17 weeks from February to May 2017 ( Figure 1B ). All measurements were transmitted wirelessly through the smartphone app to a secure database. Participants were instructed to take their BP using the Withings wireless BP monitor while sitting but were not trained or observed or given any other special instructions. For the analysis, mean arterial pressure (MAP) was calculated based on the following formula: MAP=diastolic BP +0.4 (systolic BP−diastolic BP), 17 where diastolic and systolic BP were reported by the wireless BP monitor. PWV, HR, and body mass index (BMI)/weight were measured by standing on the smart scale. Acceptable ranges of systolic and diastolic BPs were 80 to 225 and 30 to 110 mm Hg, respectively. An acceptable time between BP and PWV measurements was <1 hour. An acceptable range for PWV was 4 to 14 m/s. PWV and BP values outside the specified acceptable ranges and BP and PWV measurements taken >1 hour apart were excluded, and the individual did not receive credit for those measurements.
Participants agreed to wear activity trackers during the day and night, for at least 2 days per week, throughout the study. The accuracies of smartphone applications and wearable activity tracking devices to track physical activity have been previously reported. 18, 19 The smartphone app also recorded activity using the built-in activity trackers on the participants' smartphones. In the case of activity device failure (eg, battery exhaustion), the activity information was integrated.
Fifty-two participants used the Aura Total Sleep System to track sleep, which uses a method known as ballistocardiography, or a measurement of cardiac variability, to detect different sleep phases. 20, 21 Figure 1. Screenshots of mobile app developed for the study. A, Screenshot of invitation sent to eligible participants for study enrollment. B, Diagram used to explain the study protocol, and to obtain informed consents. C, Weekly dashboard presented to app users detailing progress and successful completion of study measurements. PWV indicates pulse wave velocity.
The Aura system has proven accuracy by comparisons with polysomnography recordings, the current gold standard. 22 Participants without an Aura device had sleep calculated by the smartphone app and wearable activity tracking devices, which has been shown to correlate strongly with research-grade devices and be of high accuracy. 23 Participants received 2 reminder messages on their smartphone each week. A weekly dashboard was provided on the smartphone app providing the number of weeks where the user successfully recorded BP, PWV, activity, and sleep measurements ( Figure 1C ). Participants were compensated with a Withings Thermo thermometer (estimated retail price: $100) at 8 weeks if requirements were met. Participants were compensated with a Withings Steel HR (estimated retail price: $180) at 17 weeks if requirements were met. Participants were allowed to miss their BP and PWV measurements 4× (weeks) in the study and still be rewarded.
Results

Demographics
Two hundred and fifty-five individuals were enrolled and started the study by measuring at least 1 PWV and BP. Two hundred and fourteen (83%) participants were male with an average age of 48.7 years (Table S2 for full demographic info). Females were roughly the same age at 47.4 years. A small number of participants had a history of stroke (n=2), myocardial infarction (n=9), and kidney disease (n=4). Sixty-seven (26%) study participants were taking antihypertensive medications. A minority of users (3.5%) had >12 alcoholic drinks per week, whereas 47% reported no alcohol use at all. Forty-three (17%) participants were taking over-the-counter medications, with nonsteroidal anti-inflammatory drugs comprising ≈90% of all medications reported.
After a High Initial Drop Out, Participant Engagement and Satisfaction Was High
Although 295 individuals responded to the push message on the mobile app and signed the digital informed consent, 40 (14%) of these individuals never recorded a BP or PWV, and 9 (3%) participants measured BP or PWV only once. This initial drop out was expected, as market research shows that 22% to 27% of smartphone users will open a downloaded app only once. 24 Of the remaining 246 study participants (that started the study), 180 (73%) of participants successfully measured BP and PWV, <1 hour apart, for at least 14 of 17 weeks, and thereby qualified for the study rewards ( Figure 2 ). In comparison, a study of 5115 participants that used a mHealth app to regularly measure BP but did not give out monetary rewards, reported that 74% were using the app at 2 weeks and only 6% at 16 weeks. 25 Individuals did not receive credit for BP and PWV measurements that were outside the specified acceptable ranges or when BP and PWV measurements were taken >1 hour apart. These failed attempts were not recorded but were filtered by the app. Table S3 for full details of adherence.
At on a scale from 1 to 10, where a 10 is considered an extremely good experience, the study scored an average of 9.1. The protocol design graded at 9.3, which was considered easy to follow. Remarkably, 99% of participants were willing to participate in another similar research study.
Study Population Device Values Match Population Means or Clinically Based Studies
The study population's values recorded or calculated by the health tracking devices are provided in 28 suggesting individuals overreport the amount of sleep they get each night. Females in the current study slept longer than males (7.7 versus 7.2 hours; P<0.0001). Sleep duration had an inverse relationship with weight and BMI but at overall low R 2 values (R 2 =0.02 and 0.01, respectively). A total of 22 475 PWV measurements were recorded in the study. Men had a higher PWV than women at 7.6 versus 7.3 m/s (P=0.04), respectively. In a subanalysis of 2207 European subjects with similar age and demographics, PWV was also greater in men (7.8 m/s) versus women (7.7 m/s; P=0.04) with comparable mean values. 29 In the current study, PWV significantly correlated with age, BP, weight/BMI, and total daily steps (Table S6 ). The strongest relationships with PWV were found with MAP (R 2 =0.13) and age (R 2 =0.20; Figure 3 ). This finding is in agreement with a clinic-based study featuring 16 867 subjects, also finding that MAP and age best predicted PWV. 29 The authors of this study calculated R 2 values ranging from 0.07 to 0.26 for MAP, and 0.31 to 0.46 for age but used full quadratic equations (a+b×age+c×age2) to improve regression equations and boister R 2 values. Alternatively, another study of 174 participants that measured PWV using an invasive method demonstrated modestly lower correlations with MAP (R 2 =0.06) and age (R 2 =0.13). 6 In our study, a linear regression model using MAP, age, weight, HR, and SD of the PWV as dependent variables predicted PWV with an overall R 2 of 0.36. A total of 22 888 BP measurements were recorded. Roughly 1 out of 3 of hypertensive participants had uncontrolled BPs (systolic greater >135 mm Hg or diastolic >85 mm Hg), which is actually below the national average at 47%. 30 Supporting strong medication adherence as the reason for higher than average BP disease control, only 1 study participant reported missing BP meds 2 to 4 days per week, and only 8 reported missing 1 to 2 days per week. As expected, participants with hypertension were found to take an average ≈1200 less steps per day (6900 versus 5700; P=0.01) and have a higher BMI (31.5 versus 28.6; P=0.003). After excluding participants on antihypertensive medications, a logistic regression model using PWV, SD PWV, and BMI could predict hypertension with an area under the curve of 0.81 (sensitivity=0.89, specificity=0.63; Figure 4 ). See Table S7 for statistical details.
As expected, standing and resting HRs taken by the weight scale, n=22 026, were significantly greater than sitting and resting HRs taken by the BP monitor (83.5 versus 71.4 bpm; P=2.2E-16; Figure S8 ). There was noted to be 449 more PWV than HR measurements recorded by the weight scale. These 2 measurements are calculated by independent algorithms, and this finding demonstrated ≈2% failure rate of the HR algorithm when the PWV is measured. 
Discussion
In this proof-of-concept study, we demonstrate that advanced mHealth technology can be used to accurately track PWV and new cardiovascular vital signs at home, while requiring minimal study personnel and no prior participant training. The study population's mean BP, PWV, HR, activity levels, sleep duration, and the interrelationships among these measurements were found to closely match reported population averages or values obtained from studies performed in controlled, clinical settings featuring research-grade devices, strongly supporting the study's methods, and accuracy the devices. The demographics of the study population, which was comprised mostly of middle-aged and older individuals, clearly demonstrates an interest of older adults, particularly older men, to adopt new health monitoring technologies.
As mentioned, there was a significant, expected initial drop-out rate in our study, with ≈17% of participants measuring BP or PWV only once or less. Yet, for those that started the study, the adherence was high, as 73% were able to successfully meet the study criteria and qualify for the rewards. A recent meta-analysis of 25 studies (10 487 Represented is a histogram of the number of participants that successfully measured blood pressure (BP) and pulse wave velocity (PWV), <1 h apart according to number of weeks in the study. For example, 49 individuals signed up for the study online, but never recorded a measurement. This is represented by the first column or 0 number of weeks. The values were measured by using mobile technology devices in conjunction with the customized mobile app, apart from the PSS scores that were obtained by surveys on the app. BMI indicates body mass index; BP, blood pressure; MAP, mean arterial pressure; PSS, Perceived Stress Scale; and PWV, pulse wave velocity. patients) showed that BP reduction through self-monitoring was most related to the intensity of the cointervention (eg, follow-up telephone conversations with study personnel). 31 Although our study maintained a relatively high adherence, we largely depended on both monitory rewards and cointerventions, that is, a reminder system and a dashboard system that provided the user updated adherence numbers. Whether this level of adherence is obtainable with no or lower monetary awards is an important question worth further investigation.
PWV is a validated measure of arterial wall stiffness and an important measure of cardiovascular health. 32 In the study, several older individuals demonstrated high PWV values despite low or normal mean BPs. PWV is the cumulative effect of multiple factors on arterial wall stiffness over time, where aging, genetics, and other factors are likely equally as important as chronic BP control. Thus, PWV provides an independent measure of cardiovascular risk that goes beyond BP control. Unfortunately, an inability to measure PWV outside of specialized clinical environments has limited its adoption in current clinical practice. To our knowledge, this is the first study to successfully assess PWV in the home environment. Supporting the plausibility and accuracy of our home PWV system, PWV values reported here closely matched the means reported by studies where PWV was measured in a clinical setting or invasively. 15, 29 Most importantly, PWV correlated strongest to the same covariates, age, and BP, with comparable R 2 values. Of interest and of obvious clinical importance, PWV in combination with BMI, that is, measurements obtained by the smart scales, was also able to accurately predict hypertension.
As expected, BP values positively correlated with age, BMI, and PWV. Yet, as demonstrated by the heat map of Figure S10 , where yellow and blue colors represent individual values that are higher and lower than population averages, such relationships do not hold true for all individuals. For example, several individuals have normal BPs, despite a high BMI, high PWV, or being of older age. Although the heterogeneity that exists between BP and these other factors or clinical characteristics is well known, it underscores the need for care providers to develop medical and lifestyle recommendations that are intentionally tailored to the individual. The physician office visit often does not provide adequate time for such an assessment using the physician-patient interview alone, but a proposed solution would be to summarize an individuals' health tracking device data and present it as cumulative report or scorecard, such as the example provided in Table 2 . An individual's scorecard could be autopopulated by health tracking technologies and used to quickly inform both the individual and his/her care provider of problem areas that need further assessment and intervention, providing greater efficiency and more meaning to the physician office visit.
There were several salient findings in this proof-of-concept study that can be used to improve and advance future mobile health tracking studies. Identified post hoc, HR was found to differ significantly between the sitting versus standing position. HR is known to increase with standing because of baroreflex activation, where proportional activation of the sympathetic nervous tract maintains BP despite orthostatism, 33, 34 but it shows that the home environment provides endless opportunities for systematical errors to occur.
In agreement with clinical studies of BP and PWV, a significant amount of the variation seen in these measurements could not be explained with the extensive array of lifestyle factors measured. It is likely that factors not easily measured, such as current emotional state or technique differences, acted together influence BP recordings, perhaps with incalculable results. This finding underscores the need for high periodicity of measurements, something that can likely only be done using out-of-office technologies, before making medical treatment decisions.
There are several important limitations to performing mHealth studies that warrant further discussion. The difficulties in sustaining user engagement, in combination with a traditionally high initial drop-out rate, are major problems for almost all mHealth studies. A recent meta-analysis of 25 studies (10 487 patients) showed that BP reduction through self-monitoring was most correlated to the intensity of the cointervention used (eg, follow-up telephone conversations with study personnel). 31 Although our study maintained a relatively high adherence rate (in comparison to similar studies), we depended on both monetary rewards and cointerventions, that is, a reminder system and a dashboard system that provided the user updated adherence numbers. The monetary rewards used in this study, to maintain 4 months of adherence, totaled >$280. Although this cost per individual is arguably <2 physician office visits in the same period (average physician visit cost=$200), while providing substantially more insight into cardiovascular vital signs, an ability to obtain funding for these mHealth endeavors will likely be a future challenge and may limit access to those of lower socioeconomic status. Furthermore, our sample size was relatively small, whereas scaling to a large population will be accompanied by increasing and unique expenses, such as the costs associated with large data storage. The use of mHealth technologies are also accompanied by intrinsic, perhaps underappreciated, challenges. Wearable activity tracker batteries may unexpectedly fail, limiting data captures. Activity trackers worn on the wrist may also falsely record the number of steps, such as during eating or other activity, and have the potential to be less accurate when individuals walk at different paces. To limit or correct for these potential problems, we allowed users to give step data recorded by their smartphone activity trackers, integrating this data with the wearable device data, improving robustness of the physical activity data. Perhaps reassuringly, a recent study found that activity devices worn on the chest, pants pocket, and wrist demonstrated good-to-excellent correlation to the gold standard, step counts during treadmill experiments when users were walking at 2.5, 5, and 8 km/h. 35 Mobile health tracking devices often change, and commercial companies may tweak software algorithms, upgrade software or device versions, integrate devices, or even discontinue product lines altogether. After the study's completion, the Nokia corporation, who bought and subsequently sold the Withings company, voluntarily deactivated the PWV feature from its smartscale, perhaps temporarily, for regulatory concern that it no longer falls under the wellness device classification. Any of these changes have to potential to disrupt or permanently stop mHealth studies.
Perspectives
In summary, we provide new evidence that new cardiovascular vital signs, including the newly adopted PWV, can be accurately measured and tracked outside of the physician office visit using new mobile health technologies, a system that requires minimal designated study or medical personnel, minimal participant training, and thereby is likely scalable to much larger populations. In our study, the home mHealth monitoring system was associated with high adherence, satisfaction, and participant engagement, which when taken together with strong indicators of accuracy, sets the stage to assess and potentially reduce cardiovascular risk in the general population.
